Eyegate Pharmaceuticals (EYEG) Sees Large Volume Increase
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) shares saw unusually-high trading volume on Monday . Approximately 759,663 shares traded hands during trading, an increase of 73% from the previous session’s volume of 440,356 shares.The stock last traded at $1.25 and had previously closed at $1.16.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective (down previously from $6.00) on shares of Eyegate Pharmaceuticals in a research note on Wednesday, November 15th.
The company has a debt-to-equity ratio of 0.01, a current ratio of 0.81 and a quick ratio of 0.81.
COPYRIGHT VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/12/11/eyegate-pharmaceuticals-eyeg-sees-large-volume-increase.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Stock Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.